Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in Moderate to Severe Atopic Dermatitis (Brazil)
NCT04666675Phase 3Withdrawn
- Sponsor
- AbbVie Inc.
- Start
- Dec 2020
- Primary completion
- Mar 2021
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of upadacitinib in atopic dermatitis (AD) (4 arms), sponsored by AbbVie Inc. Primary endpoints: Percentage of Participants Achieving at least a 75% Reduction in Eczema Area and Severity Index at 16 weeks and Number of Participants With Adverse Events at 52 weeks. Planned start Dec 2020; status: withdrawn.
02
Drugs
upadacitinib
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT04666675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04666675.